Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein

A new coronavirus associated with human respiratory disease in China

(2020) Fan Wu et al.   NATURE

A pneumonia outbreak associated with a new coronavirus of probable bat origin

(2020) Peng Zhou et al.   NATURE

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia

(2020) Qun Li et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

(2020) Daniel Wrapp et al.   SCIENCE

Transmission routes of 2019-nCoV and controls in dental practice

(2020) Xian Peng et al.   International Journal of Oral Science

Nanobody‑horseradish peroxidase and -EGFP fusions as reagents to detect porcine parvovirus in the immunoassays

(2020) Qizhong Lu et al.   JOURNAL OF NANOBIOTECHNOLOGY

Coronaviruses and SARS-CoV-2

(2020) Stephan Ludwig et al.   ANESTHESIA AND ANALGESIA

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

(2020) Daniel Wrapp et al.   CELL

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

COVID-19: towards controlling of a pandemic

(2020) Juliet Bedford et al.   LANCET

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

(2020) Markus Hoffmann et al.   MOLECULAR CELL

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

(2020) Rui Shi et al.   NATURE

Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform

(2020) Tran Thi Nhu Thao et al.   NATURE

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

(2020) Jun Lan et al.   NATURE

The coronavirus pandemic in five powerful charts

(2020) Ewen Callaway et al.   NATURE

A human monoclonal antibody blocking SARS-CoV-2 infection

(2020) Chunyan Wang et al.   Nature Communications

Fenobody and RANbody-based sandwich enzyme-linked immunosorbent assay to detect Newcastle disease virus

(2020) Pinpin Ji et al.   JOURNAL OF NANOBIOTECHNOLOGY

A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity

(2020) Jingyun Yang et al.   NATURE

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

(2020) Laura Riva et al.   NATURE

A single-domain antibody inhibits SFTSV and mitigates virus-induced pathogenesis in vivo

(2020) Xilin Wu et al.   JCI Insight

High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models

(2020) Wei Li et al.   CELL

Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination

(2020) Ariane Sternberg et al.   LIFE SCIENCES

Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate

(2020) Sandhya Bangaru et al.   SCIENCE

Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial

(2020) Steve Cunningham et al.   Lancet Respiratory Medicine

Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment

(2020) Jing Ouyang et al.   Frontiers in Immunology

Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

(2020) Wen Shi Lee et al.   Nature Microbiology

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

(2019) Marie Scully et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nanobody-horseradish peroxidase fusion protein as an ultrasensitive probe to detect antibodies against Newcastle disease virus in the immunoassay

(2019) Yamin Sheng et al.   JOURNAL OF NANOBIOTECHNOLOGY

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura

(2019) Tugrul Elverdi et al.   Drug Design Development and Therapy

Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura

(2019) Maria Laura Sargentini-Maier et al.   Expert Review of Clinical Pharmacology

The Therapeutic Potential of Nanobodies

(2019) Ivana Jovčevska et al.   BIODRUGS

A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV

(2018) Guangyu Zhao et al.   JOURNAL OF VIROLOGY

CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry

(2018) Anneleen Van Hout et al.   BIOCHEMICAL PHARMACOLOGY

Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin

(2018) Nick S. Laursen et al.   SCIENCE

Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics

(2017) Peter Bannas et al.   Frontiers in Immunology

A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells

(2017) Renée C. G. de Bruin et al.   OncoImmunology

Nanobodies as therapeutics: big opportunities for small antibodies

(2016) Sophie Steeland et al.   DRUG DISCOVERY TODAY

The Antiviral Mechanism of an Influenza A Virus Nucleoprotein-Specific Single-Domain Antibody Fragment

(2016) Leo Hanke et al.   mBio

Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

(2015) Laurent Detalle et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nanobody-based cancer therapy of solid tumors

(2015) Marta Kijanka et al.   Nanomedicine

An intracellularly expressed Nsp9-specific nanobody in MARC-145 cells inhibits porcine reproductive and respiratory syndrome virus replication

(2015) Hongliang Liu et al.   VETERINARY MICROBIOLOGY

Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins

(2014) Sheng-Fan Wang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26

(2013) Guangwen Lu et al.   NATURE